Abstract

Mutations in NIPBL are the major cause of Cornelia de Lange Syndrome (CdLS). NIPBL is the cohesin-loading factor and has recently been associated with the BET (bromodomains and extra-terminal (ET) domain) proteins BRD2 and BRD4. Related to this, a CdLS-like phenotype has been described associated to BRD4 mutations. Here, we show direct interaction of NIPBL with different BET members in yeast, and selective interaction with BRD4 in cells, being the ET domain involved in the interaction. To understand the relationship between NIPBL and BET proteins, we have performed RNA-Seq expression analysis following depletion of the different proteins. Results indicate that genes regulated by NIPBL largely overlap with those regulated by BRD4 but not with those regulated by BRD2. ChIP-Seq analysis indicates preferential NIPBL occupancy at promoters, and knockdown experiments show mutual stabilization of NIPBL and BRD4 on co-regulated promoters. Moreover, human fibroblasts from CdLS probands with mutations in NIPBL show reduced BRD4 at co-occupied promoters. Functional analysis in vivo, using mutants of Drosophila melanogaster, confirmed the genetic interaction between Nipped-B and fs(1)h, the orthologs of human NIPBL and BRD4, respectively. Thus, we provide evidence for NIPBL and BRD4 cooperation in transcriptional regulation, which should contribute to explain the recently observed CdLS-like phenotype associated with BRD4 mutations.

Highlights

  • Bromodomain and extra-terminal domain (BET) proteins are chromatin readers with an important role in cell cycle progression[1,2,3]

  • NIPBL interacts with the ET domain of BET proteins Searching for BRD2 partners, we previously performed a two-hybrid screening by testing a truncated BRD2 bait construct, which lacks the bromodomains, against an 11day-old mouse embryo cDNA library[18]

  • Two-hybrid indicated that the interaction was not restricted to BRD2, since similar constructs based on BRD3 and BRD4, interacted with NIPBL (Fig. 1b)

Read more

Summary

Introduction

Bromodomain and extra-terminal domain (BET) proteins are chromatin readers with an important role in cell cycle progression[1,2,3]. The prominent role that these proteins display in cell cycle control has boosted the development of drugs antagonizing BET proteins, as an effective therapy against a variety of cancer types[10,11]. Synthetic molecules mimicking acetyllysine groups, which are able to efficiently dissociate BET proteins from the chromatin, have been successfully used for tumors treatment in mice[12,13,14,15,16,17]. A conserved motif B (mB) accounts for protein dimerization[18], while the conserved and exclusive extra-terminal (ET) domain involved in Official journal of the Cell Death Differentiation Association

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call